Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report

Transplant Proc. 2016 Jun;48(5):1855-7. doi: 10.1016/j.transproceed.2016.01.049.

Abstract

We report a case of a 27-year-old man diagnosed with the infection of HBV delta in the 8th month of life. The treatment complied with evidence-based medical guidelines, comprising neoadiuvant chemotherapy and surgery. Liver transplantation from a deceased donor followed by chemotherapy was performed when the patient was 16 years 9 months of age because of recurrent HCC tumor. The patient qualified for immunosuppressive treatment (rapamycin, tacrolimus), lamivudine, anti-HBs globulin intravascular infusion, and anti-HBV vaccination as a prophylaxis against reinfection with HBV. In conclusion, this case demonstrates the importance of a postoperative follow-up of patients with HCC, even years after liver transplantation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular / pathology*
  • Hepatitis B / complications*
  • Hepatitis B / surgery
  • Hepatitis B virus
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lamivudine / therapeutic use
  • Liver Neoplasms / pathology*
  • Liver Transplantation*
  • Male
  • Neoplasm Recurrence, Local / pathology*
  • Recurrence
  • Tacrolimus / therapeutic use
  • Tissue Donors
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Immunosuppressive Agents
  • Lamivudine
  • Tacrolimus